Fecal microbiota transplantation — or FMT — tends to provoke strong reactions. For some patients, it represents a last resort after years of failed treatments. For others, it's an intriguing frontier they've read about online. Whatever brought you here, this guide will give you an honest picture of what FMT is, what the science actually shows, and what to expect if you're considering joining a clinical trial.
What Is FMT?
FMT is a medical procedure that involves transferring stool from a healthy, screened donor into the gut of a patient. The goal is to introduce a diverse, balanced community of gut microorganisms to replace a disrupted or depleted microbiome.
It sounds unusual. But it's been practiced in some form for centuries — and the modern, clinical version of FMT has been studied in hundreds of trials and is now FDA-approved for one condition.
What FMT Is Already Proven to Treat
In 2023, the FDA approved the first orally-administered FMT product, Vowst (SER-109), for the prevention of recurrent Clostridioides difficile (C. diff) infections. A second product, Rebyota, was approved as a rectally-administered FMT for the same indication.
C. diff is an intestinal infection that can become a vicious cycle — the antibiotics used to treat it further destroy the gut microbiome, making reinfection more likely. FMT breaks this cycle by essentially rebooting the gut with a healthy donor microbiome.
In clinical trials, FMT achieved an 88% cure rate for recurrent C. diff — dramatically better than repeated antibiotics.
What Conditions Are Being Studied in FMT Trials?
Beyond C. diff, researchers are actively testing FMT for:
Ulcerative Colitis (UC)
Several randomized controlled trials have shown that FMT can achieve remission in active UC. A landmark Australian trial found that about 32% of UC patients who received FMT achieved remission, compared to 9% who received a placebo. Larger Phase 3 trials are now underway.
Crohn's Disease
FMT for Crohn's is less studied than for UC, and results have been more variable. Early trials suggest benefit for some patients, particularly those with certain microbiome profiles. This is an active area of research.
Irritable Bowel Syndrome (IBS)
A Norwegian trial found significant symptom reduction in IBS patients treated with FMT. Multiple follow-up trials are in progress to understand which patients benefit most.
Metabolic Conditions
Researchers are testing whether FMT from lean, metabolically healthy donors can improve insulin sensitivity in people with obesity or type 2 diabetes.
Mental Health
Preliminary research suggests FMT may affect mood and anxiety through the gut-brain axis. This remains very early-stage science, but clinical trials are beginning.
How Is FMT Delivered?
In clinical trials, FMT is administered in several ways:
- Colonoscopy — the most common research method; allows FMT to reach the colon directly
- Enema — a lower-tech option that can be self-administered in some protocols
- Capsule (oral) — freeze-dried donor stool in capsule form; no procedure required
- Nasoduodenal tube — less common; FMT delivered via the small intestine
The delivery method matters. For UC and C. diff, colonoscopic delivery tends to show the best results. For metabolic conditions, oral capsules are more common.
Where Does the Donor Stool Come From?
In a clinical trial, donor stool is sourced from rigorously screened donors — typically through regulated stool banks like OpenBiome (US) or equivalent organizations. Donors are screened for dozens of pathogens, including HIV, hepatitis, parasites, and multi-drug resistant organisms.
Do not attempt DIY FMT outside of a clinical setting. The FDA has issued warnings about serious infections — including deaths — from unscreened DIY FMT.
What Are the Risks?
FMT delivered in a properly regulated clinical trial setting is generally considered safe. The most common side effects are minor gastrointestinal symptoms — cramping, bloating, or diarrhea in the days following the procedure.
Serious adverse events are rare but possible, primarily related to the endoscopy procedure itself (not the FMT).
The FDA mandates strict donor screening, which has significantly reduced the risk of transmitting infections. However, no screening protocol is 100% foolproof, and patients in trials are monitored closely.
Who Is Typically Eligible for FMT Trials?
Eligibility varies widely by trial, but common requirements include:
- A confirmed diagnosis of the condition being studied
- Failure of at least one standard treatment (for IBD trials)
- No antibiotic use in the weeks before the transplant
- No immunocompromising conditions in some protocols
- Age 18 or older (some pediatric trials exist)
The best way to check eligibility is to contact the trial site directly using the contact information on the trial listing.
What to Ask Before Enrolling
If you're seriously considering an FMT trial, bring these questions to your consultation:
- How has the donor stool been processed and tested?
- How many FMT treatments will I receive, and over what time period?
- Will I need to stop any of my current medications?
- What follow-up monitoring is included?
- Is there a placebo group, and what happens if I receive a placebo?
- What are my options if I don't respond?
The Bottom Line
FMT is no longer fringe medicine — it's an FDA-approved treatment for one condition and an active subject of hundreds of clinical trials worldwide. For patients with IBD, IBS, or recurrent C. diff who haven't found relief through standard treatments, an FMT trial may be worth exploring.
The best place to start is a conversation with a gastroenterologist familiar with microbiome research, combined with a search of currently recruiting trials.